Research progress on cellular senescence and therapeutic drugs in diabetic microvascular complications

doi:10.12092/j.issn.1009-2501.2026.04.010

Abstract

Abstract:

Diabetic microangiopathy is the earliest and most common complication of diabetes mellitus, which is characterised by impaired endothelial function of the microvessels, basement membrane thickening and microthrombosis, involving the kidneys, retina and nerves, and it is also a key factor leading to the decline in the patient’s quality of life and the shortening of life expectancy. In recent years, clinical and experimental studies have found that cellular senescence is a major risk factor for this type of disease, and cellular senescence is an irreversible state of cell cycle arrest, which participates in a variety of physiopathological processes affecting the occurrence and development of diabetic microangiopathy. This article provides a review of the mechanism of cellular senescence in the process of diabetic microangiopathy and the drugs that target cellular senescence for the treatment of diabetic microangiopathy to provide new research ideas for the prevention and treatment of diabetic microangiopathy.

Key words: diabetic microangiopathy, cellular senescence, mechanisms, drugs

CLC Number:

Jinju LI, Hao YANG, Nuobing RUAN, Qi XU, Zheng BI, Yufan LI, Fanjing WANG, Yixuan LIN, Zhaohui FANG. Research progress on cellular senescence and therapeutic drugs in diabetic microvascular complications[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 509-516.

References 60

1	Sun H, Saeedi P, Karuranga S, et al. Erratum to "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045" [Diabetes Res. Clin. Pract. 183 (2022) 109119][J]. Diabetes Res Clin Pract, 2023, 204, 110945. doi: 10.1016/j.diabres.2023.110945
2	Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157, 107843. doi: 10.1016/j.diabres.2019.107843
3	Sabanayagam C, Chee ML, Banu R, et al. Association of diabetic retinopathy and diabetic kidney disease with all-cause and cardiovascular mortality in a multiethnic Asian population[J]. JAMA Netw Open, 2019, 2 (3): e191540. doi: 10.1001/jamanetworkopen.2019.1540
4	An J, Nichols GA, Qian L, et al. Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes[J]. BMJ Open Diabetes Res Care, 2021, 9 (1): e001847. doi: 10.1136/bmjdrc-2020-001847
5	An Y, Xu BT, Wan SR, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction[J]. Cardiovasc Diabetol, 2023, 22 (1): 237. doi: 10.1186/s12933-023-01965-7
6	Wołoszyn-Durkiewicz A, Myśliwiec M. The prognostic value of inflammatory and vascular endothelial dysfunction biomarkers in microvascular and macrovascular complications in type 1 diabetes[J]. Pediatr Endocrinol Diabetes Metab, 2019, 25 (1): 28- 35. doi: 10.5114/pedm.2019.84710
7	Zochodne DW. The challenges of diabetic polyneuropathy: a brief update[J]. Curr Opin Neurol, 2019, 32 (5): 666- 675. doi: 10.1097/WCO.0000000000000723
8	López-Otín C, Blasco MA, Partridge L, et al. Hallmarks of aging: An expanding universe[J]. Cell, 2023, 186 (2): 243- 278. doi: 10.1016/j.cell.2022.11.001
9	Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: Defining a path forward[J]. Cell, 2019, 179 (4): 813- 827. doi: 10.1016/j.cell.2019.10.005
10	Jha SK, De Rubis G, Devkota SR, et al. Cellular senescence in lung cancer: Molecular mechanisms and therapeutic interventions[J]. Ageing Res Rev, 2024, 97, 102315. doi: 10.1016/j.arr.2024.102315
11	Saito Y, Yamamoto S, Chikenji TS. Role of cellular senescence in inflammation and regeneration[J]. Inflamm Regen, 2024, 44 (1): 28. doi: 10.1186/s41232-024-00342-5
12	Zhang W, Sun HS, Wang X, et al. Cellular senescence, DNA damage, and neuroinflammation in the aging brain[J]. Trends Neurosci, 2024, 47 (6): 461- 474. doi: 10.1016/j.tins.2024.04.003
13	Hayflickl Moorheadps. The serialcultivation of human diploid cellstrains[J]. Exp Cell Res, 1961, 25, 585- 621.
14	Wang B, Han J, Elisseeff JH, et al. The senescence-associated secretory phenotype and its physiological and pathological implications[J]. Nat Rev Mol Cell Biol, 2024, 25 (12): 958- 978. doi: 10.1038/s41580-024-00727-x
15	Fu H, Liu S, Bastacky SI, et al. Diabetic kidney diseases revisited: A new perspective for a new era[J]. Mol Metab, 2019, 30, 250- 263. doi: 10.1016/j.molmet.2019.10.005
16	Verzola D, Gandolfo MT, Gaetani G, et al. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy[J]. Am J Physiol Renal Physiol, 2008, 295 (5): F1563- F1573. doi: 10.1152/ajprenal.90302.2008
17	Guo H, Rogg M, Keller J, et al. ADP-ribosylation factor-interacting protein 2 acts as a novel regulator of mitophagy and autophagy in podocytes in diabetic nephropathy[J]. Antioxidants (Basel), 2024, 13 (1): 81. doi: 10.3390/antiox13010081
18	Fu B, Yang J, Chen J, et al. Preventive effect of Shenkang injection against high glucose-induced senescence of renal tubular cells[J]. Front Med, 2019, 13 (2): 267- 276. doi: 10.1007/s11684-017-0586-8
19	Cao D, Zhao M, Wan C, et al. Role of tea polyphenols in delaying hyperglycemia-induced senescence in human glomerular mesangial cells via miR-126/Akt-p53-p21 pathways[J]. Int Urol Nephrol, 2019, 51 (6): 1071- 1078. doi: 10.1007/s11255-019-02165-7
20	Cao DW, Jiang CM, Wan C, et al. Upregulation of miR-126 delays the senescence of human glomerular mesangial cells induced by high glucose via telomere-p53-p21-Rb signaling pathway[J]. Curr Med Sci, 2018, 38 (5): 758- 764. doi: 10.1007/s11596-018-1942-x
21	Yamagishi S, Nakamura N, Suematsu M, et al. Advanced glycation end products: A molecular target for vascular complications in diabetes[J]. Mol Med, 2015, 21 (S1): S32- S40. doi: 10.2119/molmed.2015.00067
22	Kan WC, Hwang JY, Chuang LY, et al. Effect of osthole on advanced glycation end products-induced renal tubular hypertrophy and role of klotho in its mechanism of action[J]. Phytomedicine, 2019, 53, 205- 212. doi: 10.1016/j.phymed.2018.09.030
23	Zhang X, Chen X, Wu D, et al. Downregulation of connexin 43 expression by high glucose induces senescence in glomerular mesangial cells[J]. J Am Soc Nephrol, 2006, 17 (6): 1532- 1542. doi: 10.3410/f.13983.471489
24	Liu J, Yang JR, Chen XM, et al. Impact of ER stress-regulated ATF4/p16 signaling on the premature senescence of renal tubular epithelial cells in diabetic nephropathy[J]. Am J Physiol Cell Physiol, 2015, 308 (8): C621- C630. doi: 10.1152/ajpcell.00096.2014
25	Chen K, Dai H, Yuan J, et al. Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy[J]. Cell Death Dis, 2018, 9 (2): 105. doi: 10.1038/s41419-017-0127-z
26	Korolchuk VI, Miwa S, Carroll B, et al. Mitochondria in cell senescence: Is mitophagy the weakest link?[J]. E Bio Medicine, 2017, 21, 7- 13. doi: 10.1016/j.ebiom.2017.03.020
27	Troyano-Suárez N, del Nogal-Avila M, Mora I, et al. Glucose oxidase induces cellular senescence in immortal renal cells through ILK by downregulating Klotho gene expression[J]. Oxid Med Cell Longev, 2015, 2015, 416738. doi: 10.1155/2016/8392708
28	Yeh TH, Tu KC, Wang HY, et al. From acute to chronic: Unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease[J]. Int J Mol Sci, 2024, 25 (3): 1755. doi: 10.3390/ijms25031755
29	Zhang S, Cai G, Fu B, et al. SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence[J]. Mech Ageing Dev, 2012, 133 (6): 387- 400. doi: 10.1016/j.mad.2012.04.005
30	Gong W, Luo C, Peng F, et al. Brahma-related gene-1 promotes tubular senescence and renal fibrosis through Wnt/β-catenin/autophagy axis[J]. Clin Sci (Lond), 2021, 135 (15): 1873- 1895. doi: 10.1042/CS20210447
31	Crespo-Garcia S, Tsuruda PR, Dejda A, et al. Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition[J]. Cell Metab, 2021, 33 (4): 818- 832. doi: 10.1016/j.cmet.2021.01.011
32	Zhang S, Chen S, Sun D, et al. TIN2-mediated reduction of mitophagy induces RPE senescence under high glucose[J]. Cell Signal, 2024, 119, 111188. doi: 10.1016/j.cellsig.2024.111188
33	Peng H, Han W, Ma B, et al. Autophagy and senescence of rat retinal precursor cells under high glucose[J]. Front Endocrinol (Lausanne), 2023, 13, 1047642. doi: 10.3389/fendo.2022.1047642
34	Liu J, Chen S, Biswas S, et al. Glucose-induced oxidative stress and accelerated aging in endothelial cells are mediated by the depletion of mitochondrial SIRTs[J]. Physiol Rep, 2020, 8 (3): e14331. doi: 10.14814/phy2.14331
35	Mortuza R, Chen S, Feng B, et al. High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway[J]. PLoS One, 2013, 8 (1): e54514. doi: 10.1371/journal.pone.0054514
36	Cheng Y, Zhang M, Xu R, et al. p53 accelerates endothelial cell senescence in diabetic retinopathy by enhancing FoxO3a ubiquitylation and degradation via UBE2L6[J]. Exp Gerontol, 2024, 188, 112391. doi: 10.1016/j.exger.2024.112391
37	Sun D, Li S, Chen S, et al. TRIM25 inhibition attenuates inflammation, senescence, and oxidative stress in microvascular endothelial cells induced by hyperglycemia[J]. Graefes Arch Clin Exp Ophthalmol, 2024, 262 (1): 81- 91. doi: 10.1007/s00417-023-06160-8
38	Chen Q, Tang L, Xin G, et al. Oxidative stress mediated by lipid metabolism contributes to high glucose-induced senescence in retinal pigment epithelium[J]. Free Radic Biol Med, 2019, 130, 48- 58. doi: 10.1016/j.freeradbiomed.2018.10.419
39	Sardella-Silva G, Mietto BS, Ribeiro-Resende VT. Four seasons for Schwann cell biology, revisiting key periods: development, homeostasis, repair, and aging[J]. Biomolecules, 2021, 11 (12): 1887. doi: 10.3390/biom11121887
40	Kohlmeyer JL, Kaemmer CA, Umesalma S, et al. RABL6A regulates Schwann cell senescence in an RB1-dependent manner[J]. Int J Mol Sci, 2021, 22 (10): 5367. doi: 10.3390/ijms22105367
41	Lin HS, Yang CH, Yin TC, et al. Addition of adipose tissue-derived mesenchymal stem cells improves empagliflozin therapy for alleviating hyperglycemia--induced neuropathy [J]. Am J Transl Res, 2023, 15(10): 6264-6285.
42	Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease[J]. EBioMedicine, 2019, 47, 446- 456. doi: 10.1016/j.ebiom.2019.08.069
43	Jiang X, Ruan XL, Xue YX, et al. Metformin reduces the senescence of renal tubular epithelial cells in diabetic nephropathy via the MBNL1/miR-130a-3p/STAT3 pathway[J]. Oxid Med Cell Longev, 2020, 2020, 8708236. doi: 10.1155/2020/8708236
44	Eleftheriadis T, Pissas G, Filippidis G, et al. Dapagliflozin prevents high-glucose-induced cellular senescence in renal tubular epithelial cells[J]. Int J Mol Sci, 2022, 23 (24): 16107. doi: 10.3390/ijms232416107
45	Kim MN, Moon JH, Cho YM. Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation[J]. Diabetes Obes Metab, 2021, 23 (11): 2561- 2571.
46	Wang Z, Han N, Zhao K, et al. Protective effects of pyrroloquinoline quinine against oxidative stress-induced cellular senescence and inflammation in human renal tubular epithelial cells via Keap1/Nrf2 signaling pathway[J]. Int Immunopharmacol, 2019, 72, 445- 453. doi: 10.1016/j.intimp.2019.04.040
47	Fang X, Huang W, Sun Q, et al. Melatonin attenuates cellular senescence and apoptosis in diabetic nephropathy by regulating STAT3 phosphorylation[J]. Life Sci, 2023, 332, 122108. doi: 10.1016/j.lfs.2023.122108
48	Coughlan MT, Ziemann M, Laskowski A, et al. Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors[J]. Sci Rep, 2022, 12 (1): 20278. doi: 10.1038/s41598-022-24851-w
49	Zheng S, Geng R, Guo J, et al. Oleuropein supplementation ameliorates long-course diabetic nephropathy and diabetic cardiomyopathy induced by advanced stage of type 2 diabetes in db/db mice[J]. Nutrients, 2024, 16 (6): 848. doi: 10.3390/nu16060848
50	Fang Y, Chen B, Gong AY, et al. The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults[J]. Kidney Int, 2021, 100 (5): 1037- 1053. doi: 10.1016/j.kint.2021.06.031
51	Abharzanjani F, Hemmati M. Protective effects of quercetin and resveratrol on aging markers in kidney under high glucose condition: in vivo and in vitro analysis[J]. Mol Biol Rep, 2021, 48 (7): 5435- 5442. doi: 10.1007/s11033-021-06550-3
52	Cheng YW, Huang YC, Chang KF, et al. Protective effect of curcumin on the tight junction integrity and cellular senescence in human retinal pigment epithelium of early diabetic retinopathy[J]. J Physiol Investig, 2024, 67 (3): 107- 117. doi: 10.4103/ejpi.EJPI-D-23-00035
53	Huang YC, Chen BC, Chang KF, et al. The alleviation effects of n-butylidenephthalide on apoptosis, senescence, and tight junction impairment of retinal pigment epithelium by activating Nrf-2/HO-1 signaling pathway in early diabetic retinopathy[J]. Life Sci, 2023, 327, 121815. doi: 10.1016/j.lfs.2023.121815
54	Hou L, Du J, Dong Y, et al. Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathy[J]. Hum Cell, 2024, 37 (3): 666- 674. doi: 10.1007/s13577-024-01038-1
55	Nian S, Mi Y, Ren K, et al. The inhibitory effects of Dulaglutide on cellular senescence against high glucose in human retinal endothelial cells[J]. Hum Cell, 2022, 35 (4): 995- 1004. doi: 10.1007/s13577-022-00703-7
56	Zhou X, Wang L, Zhang Z, et al. Fluorometholone inhibits high glucose-induced cellular senescence in human retinal endothelial cells [J]. Hum Exp Toxicol, 2022, 41: 9603271221076107.
57	Gericke A, Suminska-Jasińska K, Bręborowicz A. Sulodexide reduces glucose induced senescence in human retinal endothelial cells[J]. Sci Rep, 2021, 11 (1): 11532. doi: 10.1038/s41598-021-90987-w
58	Crespo-Garcia S, Fournier F, Diaz-Marin R, et al. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results[J]. Nat Med, 2024, 30 (2): 443- 454. doi: 10.1038/s41591-024-02802-4
59	Song J, Lee B, Kang S, et al. Agmatine ameliorates high glucose-induced neuronal cell senescence by regulating the p21 and p53 signaling[J]. Exp Neurobiol, 2016, 25 (1): 24- 32. doi: 10.5607/en.2016.25.1.24
60	Zhu WW, Xiao F, Tang YY, et al. Spermidine prevents high glucose-induced senescence in HT-22 cells by upregulation of CB1 receptor[J]. Clin Exp Pharmacol Physiol, 2018, 45 (8): 832- 840. doi: 10.1111/1440-1681.12955

[1]	Yanan CHEN, Yaru YANG, Chen JIANG, Feng YAO, Ke WANG, Renpeng ZHOU, Yingjie ZHAO, Wei HU. Precision medication analysis based on the detection of neurological and psychotropic drug gene polymorphisms in 36 patients using MALDI-TOF-MS technology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 344-351.
[2]	Furui WANG, Tian HUANG, Wenli JIANG, Zenan HU. Therapeutic advances in small-molecule drugs for moderate-to-severe ulcerative colitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 392-399.
[3]	SUN Min, WANG Hongya, HE Hongbo, ZHU Zhiming, GAO Peng. Research and progress in the treatment of cardiovascular diseases with metabolic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 984-997.
[4]	CAO Shang, RAO Yuqing, DONG Chenglong, LI Ziwei, KAN Hongwei. Pharmacovigilance of antibody drugs: Bayesian network practice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(11): 1541-1549.
[5]	TIAN Jiexiang, QI Wenxia, WANG Gang, YAN Yanfeng, WANG Zhandong, WEI Yong, LIU Hailong, ZHANG Yuanyuan. Advances in the study of the pathological role of salivary gland epithelial cells in Sj?gren's syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(11): 1550-1558.
[6]	ZHANG Li, LU Chang, AN Minghui, WANG Mengmeng, ZONG Xiaoyu, YU Lin, RAN Zhuo-ling, SONG Jing, LI Huijie, GONG Jian. Mechanism of action and research progress of vaccine adjuvants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(7): 785-791.
[7]	LIU Qian, ZHANG Jianing, ZHANG Shuang, LIU Qinglan, ZHANG Baoyin, SUN Nan. Comparison of clinical effectiveness and safety between generic and branded dienogest tablets in the treatment of endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(5): 527-534.
[8]	MOU Duo, LIU Kexin, CHANG Chun. Value of biotargeted drugs in airway mucus therapy of asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(4): 423-426.
[9]	LI Size, HUANG Qi, WU Xiaojie, WANG Shaonan, GUAN Yihui, XIE Fang, ZHANG Jing. The application of positron emission tomography in the research and development of central nervous system drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(3): 316-327.
[10]	XIE Ran, CHENG Lu, ZHOU Shuang, ZHANG Xueyuan, WANG Xiaoru, ZHAO Xia, HE Xu, ZHAO Nan, JIA Bo, CUI Yimin. Pharmacokinetics and bioequivalence of rivaroxaban tablet in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(11): 1295-1299.
[11]	WAN Shujun, ZHANG Mengying, CHEN Qilei, ZHONG Min, ZHU Xiaolong, ZHANG Yingying, LV Kun. Clinical value of genetic polymorphism analysis of hypertension drugs for individualized treatment of hypertension patients in the southern Anhui region [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(1): 68-75.
[12]	ZHAO Quanming, YANG Mandou, HU Yibo, SU Youtong, PU Li, ZHANG Yu, LI Wenliang. Research progress on drug treatment and drug resistance mechanism of gastrointestinal stromal tumors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(1): 82-89.
[13]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[14]	DANG Zilong, LIU Haiyang, ZHANG Yangfan, LIU Jinfeng, ZHANG Tianwei, LI Bin, GUO Hong, CHENG Wenyuan, XU Xiaohui, LI Yile, WEI Yuhui, WU Xin'an. Optimization strategy of antibiotic dosing regimen in intensive care unit patients with augmented renal clearance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 561-571.
[15]	ZHANG Mingkang, MA Yanrong, JIN Yongwen, ZHOU Yan, CUI Ruirui, WU Xin'an. Advances in clinical research on drug-induced acute interstitial nephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 419-428.